Investors

Webcast ImageWebcast
Geron at Stifel 2017 Healthcare Conference (Replay)
11/14/17
Geron at Stifel 2017 Healthcare Conference
Tuesday, November 14, 2017 
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast
Geron at Piper Jaffray 29th Annual Healthcare Conference  (Live)
11/28/17
Geron at Piper Jaffray 29th Annual Healthcare Conference
Tuesday, November 28, 2017 
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Corporate Profile
Geron is a clinical stage biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Imetelstat is currently being tested in two clinical trials: IMbark™, a Phase 2 trial in myelofibrosis (MF) and IMerge™, a Phase 2/3 trial in myelodysplastic syndromes (MDS). These clinical trials are being conducted by Janssen Biotech, Inc., under a collaboration and license agreement, in which Janssen were granted the exclusive rights to develop and commercialize imetelstat worldwide for all indications in oncology, including hematologic myeloid malignancies, and all other human therapeutic uses.

Telomerase is an enzyme that enables cancer cells, including malignant progenitor cells, to maintain telomere length, which provides them with the capacity for limitless, uncontrolled proliferation. Using Geron’s proprietary nucleic acid chemistry, imetelstat was designed as an oligonucleotide that targets and binds with high affinity to the active site of telomerase, thereby directly inhibiting telomerase activity and impeding malignant cell proliferation. Early clinical data, including molecular responses in essential thrombocythemia (ET) and remissions, including reversal of bone marrow fibrosis in MF, suggest imetelstat may have disease-modifying activity by inhibiting the progenitor cells of the malignant clones for the underlying diseases.
Recent NewsMore >>
DateTitle 
Nov 20, 2017Geron Announces First Patient Dosed in Expanded Part 1 of IMerge Clinical Trial in Myelodysplastic SyndromesPrinter Friendly Version
Nov 7, 2017Geron Announces November Investor Conference Presentation WebcastsPrinter Friendly Version
Nov 1, 2017Geron Corporation Reports Third Quarter 2017 Financial ResultsPrinter Friendly Version
Upcoming EventsMore >>
DateTitle
11/28/17
Geron at Piper Jaffray 29th Annual Healthcare Conference
Corporate Presentation
Download Documentation Cantor Fitzgerald 2017 Presentation
Stock Information
GERN (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$1.90
Change (%) Stock is Down 0.02 (1.04%)
Volume1,035,353
Data as of Nov 20, 2017 4:00 p.m. ET
Refresh quote
Data provided by Nasdaq. Minimum 15 minutes delayed.
Contact Information

Anna Krassowska, Ph.D.
E-mail: investor@geron.com

 Print Page |  E-mail Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts